🇺🇸 FDA

Intelligence Platform

Patents

Browse 33 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12364683

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12138247

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12109196

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12090140

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11998529

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11998528

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11931340

Use of sublingual dexmedetomidine for the treatment of agitation

BioXcel Therapeutics, Inc. · Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11890272

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11839604

Use of sublingual dexmedetomidine for the treatment of agitation

BioXcel Therapeutics, Inc. · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11806429

Film formulations containing dexmedetomidine and methods of producing them

BioXcel Therapeutics, Inc. · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11806334

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786508

Use of sublingual dexmedetomidine for the treatment of agitation

BioXcel Therapeutics, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11559484

Film formulations containing dexmedetomidine and methods of producing them

BioXcel Therapeutics, Inc. · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11517524

Film formulations containing dexmedetomidine and methods of producing them

BioXcel Therapeutics, Inc. · Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11497711

Film formulations containing dexmedetomidine and methods of producing them

BioXcel Therapeutics, Inc. · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11478422

Film formulations containing dexmedetomidine and methods of producing them

BioXcel Therapeutics, Inc. · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11253591

Combination of lenalidomide and polypeptide construct, and uses thereof

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10836721

Thalidomide analogs and methods of use

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10792246

Film formulations containing dexmedetomidine and methods of producing them

BioXcel Therapeutics, Inc. · Granted Tue Oct 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10730835

Thalidomide analogs and methods of use

The United States of America, as represented by the Secretary, Health and Human Services · Granted Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10342869

Compositions comprising anti-CD38 antibodies and lenalidomide

The Regents of the University of California · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10232041

Combination of lenalidomide and polypeptide construct, and uses thereof

TEVA PHARMACEUTICALS PTY LTD · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9814706

Hydrobromide salt of pridopidine

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Nov 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9636334

Combination of lenalidomide and polypeptide construct, and uses thereof

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted